Ryman-Rasmussen Jessica P, Nichols David E, Mailman Richard B
Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7160, USA.
Mol Pharmacol. 2005 Oct;68(4):1039-48. doi: 10.1124/mol.105.012153. Epub 2005 Jun 28.
Structurally dissimilar dopamine D(1) receptor agonists were compared with dopamine in their ability to activate adenylate cyclase and to internalize hemagglutinin-tagged human D(1) receptors in a stably transfected human embryonic kidney cell line. Thirteen dopamine D(1) receptor agonists were selected rationally from three different structural classes: rigid fused ring compounds [dihydrexidine, dinapsoline, dinoxyline, apomorphine, and (5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1-ena[c]-phenanthrene-9,10-diol (A86929)]; isochromans [(1R,3S)-3-(1'adamantyl)-1-aminomethyl-3,4-dihydo-5,6-dihydroxy-1H-2-benzopyran (A77636) and (1R,3S)-3-phenyl-1-aminomethyl-3,4-dihydo-5,6-dihydroxy-1H-2-benzopyran (A68930)]; and benzazepines [7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF38393), (+/-)-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF77434), 6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF82958), 3-methyl-6-chloro-7,8-hydroxy-1-[3-methylphenyl]-2,3,4,5-tetrahydro-]H-3-benzazepine (SKF83959), R(+)-6-chloro-7,8,-dihydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF82957), and R(+)-6-chloro-7,8,-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF81297)]. The working hypothesis was that some agonists have differential effects on adenylate cyclase versus receptor internalization that could be correlated to the structural class of the agonist. First, the affinity for the hemagglutinin-hD(1) receptor and the intrinsic activity and potency of adenylate cyclase activation were determined for each compound. The internalization time course and internalization efficacy were then determined for each agonist. It was surprising that internalization efficacy was found to be independent of either agonist structural class or affinity. Only agonists that had both high adenylate cyclase functional potency and high intrinsic activity caused internalization. In addition, four agonists from two structural classes were identified that were capable of fully activating adenylate cyclase without eliciting an internalization response. This study provides the first extensive characterization of D(1) receptor internalization in response to structurally diverse agonists and, at least for the D(1) receptor, shows that functional selectivity is not predictable by simple structural examination. These data are consistent with the hypothesis that functional selectivity reflects subtle ligand-induced conformational changes as opposed to simple agonist trafficking among discrete receptor active states.
在一个稳定转染的人胚肾细胞系中,比较了结构不同的多巴胺D(1)受体激动剂与多巴胺激活腺苷酸环化酶以及使血凝素标记的人D(1)受体内化的能力。从三种不同结构类型中合理选择了13种多巴胺D(1)受体激动剂:刚性稠环化合物[二氢瑞香素、地那索林、地诺昔林、阿扑吗啡和(5aR,11bS)-4,5,5a,6,7,11b-六氢-2-丙基-3-硫杂-5-氮杂环戊-1-烯并[c]-菲-9,10-二醇(A86929)];异色满[(1R,3S)-3-(1'-金刚烷基)-1-氨甲基-3,4-二氢-5,6-二羟基-1H-2-苯并吡喃(A77636)和(1R,3S)-3-苯基-1-氨甲基-3,4-二氢-5,6-二羟基-1H-2-苯并吡喃(A68930)];以及苯并氮杂卓[7,8-二羟基-1-苯基-2,3,4,5-四氢-1H-3-苯并氮杂卓(SKF38393)、(±)-7,8-二羟基-3-烯丙基-1-苯基-2,3,4,5-四氢-1H-3-苯并氮杂卓(SKF77434)、6-氯-7,8-二羟基-3-烯丙基-1-苯基-2,3,4,5-四氢-1H-3-苯并氮杂卓(SKF82958)、3-甲基-6-氯-7,8-羟基-1-[3-甲基苯基]-2,3,4,5-四氢-]H-3-苯并氮杂卓(SKF83959)、R(+)-6-氯-7,8,-二羟基-3-甲基-1-苯基-2,3,4,5-四氢-1H-3-苯并氮杂卓(SKF82957)和R(+)-6-氯-7,8,-二羟基-1-苯基-2,3,4,5-四氢-1H-3-苯并氮杂卓(SKF81297)]。工作假设是,一些激动剂对腺苷酸环化酶与受体内化有不同影响,这可能与激动剂的结构类型相关。首先,测定了每种化合物对血凝素-hD(1)受体的亲和力以及腺苷酸环化酶激活的内在活性和效价。然后确定了每种激动剂的内化时间进程和内化效率。令人惊讶的是,发现内化效率与激动剂结构类型或亲和力均无关。只有那些具有高腺苷酸环化酶功能效价和高内在活性的激动剂才会引起内化。此外,还鉴定出两种结构类型中的四种激动剂,它们能够完全激活腺苷酸环化酶而不引发内化反应。这项研究首次全面表征了D(1)受体对结构多样的激动剂的内化反应,并且至少对于D(1)受体而言,表明功能选择性不能通过简单的结构检查来预测。这些数据与功能选择性反映微妙的配体诱导构象变化而非简单的激动剂在离散受体活性状态之间的转运这一假设一致。